Allergan makes major urology acquisition
This article was originally published in Scrip
Allergan has acquired development and commercialization rights to interstitial cystitis/ bladder pain syndrome therapy LiRIS (lidocaine) from Taris Biomedical.
You may also be interested in...
The Bone, Reproductive and Urologic Drugs Advisory Committee will consider endpoints, clinical trial designs and other issues related to development in the disease.
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.